U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C10H17N
Molecular Weight 151.2491
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of AMANTADINE

SMILES

C1C2CC3CC1CC(C2)(C3)N

InChI

InChIKey=DKNWSYNQZKUICI-UHFFFAOYSA-N
InChI=1S/C10H17N/c11-10-4-7-1-8(5-10)3-9(2-7)6-10/h7-9H,1-6,11H2

HIDE SMILES / InChI

Molecular Formula C10H17N
Molecular Weight 151.2491
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Amantadine hydrochloride has pharmacological actions as both an anti-Parkinson and an antiviral drug. The mechanism by which amantadine exerts its antiviral activity is not clearly understood. It appears to mainly prevent the release of infectious viral nucleic acid into the host cell by interfering with the function of the transmembrane domain of the viral M2 protein. In certain cases, amantadine is also known to prevent virus assembly during virus replication. It does not appear to interfere with the immunogenicity of inactivated influenza A virus vaccine. The mechanism of action of amantadine in the treatment of Parkinson's disease and drug-induced extrapyramidal reactions is not known. Data from earlier animal studies suggest that amantadine hydrochloride may have direct and indirect effects on dopamine neurons. More recent studies have demonstrated that amantadine is a weak, non-competitive NMDA receptor antagonist (K1 = 10µM). Although amantadine has not been shown to possess direct anticholinergic activity in animal studies, clinically, it exhibits anticholinergic-like side effects such as dry mouth, urinary retention, and constipation. Amantadine was approved by the FDA in 1966 as a prophylactic agent against Asian influenza, and eventually received approval for the treatment of influenza virus A in adults. In 1969, it was also discovered by accident to help reduce symptoms of Parkinson's disease, drug-induced extrapyramidal syndromes, and akathisia.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
10.0 µM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
MANTADINE HYDROCHLORIDE

Approved Use

Amantadine Hydrochloride Capsules, USP are indicated for the prophylaxis and treatment of signs and symptoms of infection caused by various strains of influenza A virus. Amantadine Hydrochloride Capsules, USP are also indicated in the treatment of parkinsonism and drug-induced extrapyramidal reactions.

Launch Date

5.40518384E11
Primary
MANTADINE HYDROCHLORIDE

Approved Use

Amantadine Hydrochloride Capsules, USP are indicated for the prophylaxis and treatment of signs and symptoms of infection caused by various strains of influenza A virus. Amantadine Hydrochloride Capsules, USP are also indicated in the treatment of parkinsonism and drug-induced extrapyramidal reactions.

Launch Date

5.40518384E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
636.2 ng/mL
100 mg 2 times / day multiple, oral
dose: 100 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
AMANTADINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
0.24 μg/mL
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
AMANTADINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
6413.6 ng × h/mL
100 mg 2 times / day multiple, oral
dose: 100 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
AMANTADINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
14.7 h
100 mg 2 times / day multiple, oral
dose: 100 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
AMANTADINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
33%
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
AMANTADINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
0.8 g single, oral
Overdose
Dose: 0.8 g
Route: oral
Route: single
Dose: 0.8 g
Sources: Page: p.120
healthy, 2
n = 1
Health Status: healthy
Age Group: 2
Sex: M
Population Size: 1
Sources: Page: p.120
Disc. AE: Status epilepticus, Agitation...
AEs leading to
discontinuation/dose reduction:
Status epilepticus
Agitation
Diaphoresis
Vomiting
Sources: Page: p.120
3000 mg single, oral
Overdose
Dose: 3000 mg
Route: oral
Route: single
Dose: 3000 mg
Sources: Page: p.757
unhealthy, 23
n = 1
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 23
Sex: M
Population Size: 1
Sources: Page: p.757
Disc. AE: CNS toxicity...
AEs leading to
discontinuation/dose reduction:
CNS toxicity (grade 5)
Sources: Page: p.757
10 g single, oral
Overdose
Dose: 10 g
Route: oral
Route: single
Dose: 10 g
Co-administed with::
diphenhydramine, p.o(250 mg, single)
Sources: Page: p.174
unhealthy, 47
n = 1
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 47
Sex: F
Population Size: 1
Sources: Page: p.174
Disc. AE: Ventricular tachycardia...
AEs leading to
discontinuation/dose reduction:
Ventricular tachycardia
Sources: Page: p.174
274 mg 1 times / day multiple, oral
Recommended
Dose: 274 mg, 1 times / day
Route: oral
Route: multiple
Dose: 274 mg, 1 times / day
Sources: Page: p.605
unhealthy, 53.3
n = 27
Health Status: unhealthy
Condition: Multiple sclerosis
Age Group: 53.3
Sex: M+F
Population Size: 27
Sources: Page: p.605
Disc. AE: Serotonin syndrome, Dry mouth...
AEs leading to
discontinuation/dose reduction:
Serotonin syndrome (serious, 3.7%)
Dry mouth (3.7%)
Sources: Page: p.605
274 mg 1 times / day multiple, oral
Recommended
Dose: 274 mg, 1 times / day
Route: oral
Route: multiple
Dose: 274 mg, 1 times / day
Sources:
unhealthy, 63.9
n = 63
Health Status: unhealthy
Condition: Levodopa-Induced Dyskinesia in Parkinson Disease
Age Group: 63.9
Sex: M+F
Population Size: 63
Sources:
DLT: Visual hallucinations...
Disc. AE: Visual hallucinations, Peripheral edema...
Dose limiting toxicities:
Visual hallucinations (4.8%)
AEs leading to
discontinuation/dose reduction:
Visual hallucinations (7.9%)
Peripheral edema (4.8%)
Dry mouth (4.8%)
Sources:
420 mg 1 times / day multiple, oral
Highest studied dose
Dose: 420 mg, 1 times / day
Route: oral
Route: multiple
Dose: 420 mg, 1 times / day
Sources: Page: p.793
unhealthy, 66.4
n = 20
Health Status: unhealthy
Condition: Levodopa-Induced Dyskinesia in Parkinson Disease
Age Group: 66.4
Sex: M+F
Population Size: 20
Sources: Page: p.793
Disc. AE: Hallucinations, Balance disorder...
AEs leading to
discontinuation/dose reduction:
Hallucinations (15%)
Balance disorder (5%)
Confusional state (5%)
Dry mouth (5%)
Subdural hematoma (5%)
Constipation (5%)
Sources: Page: p.793
100 mg 3 times / day steady, oral
Dose: 100 mg, 3 times / day
Route: oral
Route: steady
Dose: 100 mg, 3 times / day
Sources:
unhealthy
n = 36
Health Status: unhealthy
Condition: Parkinson's disease
Population Size: 36
Sources:
Other AEs: Dry mouth...
Other AEs:
Dry mouth (below serious, 4 patients)
Sources:
AEs

AEs

AESignificanceDosePopulation
Agitation Disc. AE
0.8 g single, oral
Overdose
Dose: 0.8 g
Route: oral
Route: single
Dose: 0.8 g
Sources: Page: p.120
healthy, 2
n = 1
Health Status: healthy
Age Group: 2
Sex: M
Population Size: 1
Sources: Page: p.120
Diaphoresis Disc. AE
0.8 g single, oral
Overdose
Dose: 0.8 g
Route: oral
Route: single
Dose: 0.8 g
Sources: Page: p.120
healthy, 2
n = 1
Health Status: healthy
Age Group: 2
Sex: M
Population Size: 1
Sources: Page: p.120
Status epilepticus Disc. AE
0.8 g single, oral
Overdose
Dose: 0.8 g
Route: oral
Route: single
Dose: 0.8 g
Sources: Page: p.120
healthy, 2
n = 1
Health Status: healthy
Age Group: 2
Sex: M
Population Size: 1
Sources: Page: p.120
Vomiting Disc. AE
0.8 g single, oral
Overdose
Dose: 0.8 g
Route: oral
Route: single
Dose: 0.8 g
Sources: Page: p.120
healthy, 2
n = 1
Health Status: healthy
Age Group: 2
Sex: M
Population Size: 1
Sources: Page: p.120
CNS toxicity grade 5
Disc. AE
3000 mg single, oral
Overdose
Dose: 3000 mg
Route: oral
Route: single
Dose: 3000 mg
Sources: Page: p.757
unhealthy, 23
n = 1
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 23
Sex: M
Population Size: 1
Sources: Page: p.757
Ventricular tachycardia Disc. AE
10 g single, oral
Overdose
Dose: 10 g
Route: oral
Route: single
Dose: 10 g
Co-administed with::
diphenhydramine, p.o(250 mg, single)
Sources: Page: p.174
unhealthy, 47
n = 1
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 47
Sex: F
Population Size: 1
Sources: Page: p.174
Dry mouth 3.7%
Disc. AE
274 mg 1 times / day multiple, oral
Recommended
Dose: 274 mg, 1 times / day
Route: oral
Route: multiple
Dose: 274 mg, 1 times / day
Sources: Page: p.605
unhealthy, 53.3
n = 27
Health Status: unhealthy
Condition: Multiple sclerosis
Age Group: 53.3
Sex: M+F
Population Size: 27
Sources: Page: p.605
Serotonin syndrome serious, 3.7%
Disc. AE
274 mg 1 times / day multiple, oral
Recommended
Dose: 274 mg, 1 times / day
Route: oral
Route: multiple
Dose: 274 mg, 1 times / day
Sources: Page: p.605
unhealthy, 53.3
n = 27
Health Status: unhealthy
Condition: Multiple sclerosis
Age Group: 53.3
Sex: M+F
Population Size: 27
Sources: Page: p.605
Visual hallucinations 4.8%
DLT
274 mg 1 times / day multiple, oral
Recommended
Dose: 274 mg, 1 times / day
Route: oral
Route: multiple
Dose: 274 mg, 1 times / day
Sources:
unhealthy, 63.9
n = 63
Health Status: unhealthy
Condition: Levodopa-Induced Dyskinesia in Parkinson Disease
Age Group: 63.9
Sex: M+F
Population Size: 63
Sources:
Dry mouth 4.8%
Disc. AE
274 mg 1 times / day multiple, oral
Recommended
Dose: 274 mg, 1 times / day
Route: oral
Route: multiple
Dose: 274 mg, 1 times / day
Sources:
unhealthy, 63.9
n = 63
Health Status: unhealthy
Condition: Levodopa-Induced Dyskinesia in Parkinson Disease
Age Group: 63.9
Sex: M+F
Population Size: 63
Sources:
Peripheral edema 4.8%
Disc. AE
274 mg 1 times / day multiple, oral
Recommended
Dose: 274 mg, 1 times / day
Route: oral
Route: multiple
Dose: 274 mg, 1 times / day
Sources:
unhealthy, 63.9
n = 63
Health Status: unhealthy
Condition: Levodopa-Induced Dyskinesia in Parkinson Disease
Age Group: 63.9
Sex: M+F
Population Size: 63
Sources:
Visual hallucinations 7.9%
Disc. AE
274 mg 1 times / day multiple, oral
Recommended
Dose: 274 mg, 1 times / day
Route: oral
Route: multiple
Dose: 274 mg, 1 times / day
Sources:
unhealthy, 63.9
n = 63
Health Status: unhealthy
Condition: Levodopa-Induced Dyskinesia in Parkinson Disease
Age Group: 63.9
Sex: M+F
Population Size: 63
Sources:
Hallucinations 15%
Disc. AE
420 mg 1 times / day multiple, oral
Highest studied dose
Dose: 420 mg, 1 times / day
Route: oral
Route: multiple
Dose: 420 mg, 1 times / day
Sources: Page: p.793
unhealthy, 66.4
n = 20
Health Status: unhealthy
Condition: Levodopa-Induced Dyskinesia in Parkinson Disease
Age Group: 66.4
Sex: M+F
Population Size: 20
Sources: Page: p.793
Balance disorder 5%
Disc. AE
420 mg 1 times / day multiple, oral
Highest studied dose
Dose: 420 mg, 1 times / day
Route: oral
Route: multiple
Dose: 420 mg, 1 times / day
Sources: Page: p.793
unhealthy, 66.4
n = 20
Health Status: unhealthy
Condition: Levodopa-Induced Dyskinesia in Parkinson Disease
Age Group: 66.4
Sex: M+F
Population Size: 20
Sources: Page: p.793
Confusional state 5%
Disc. AE
420 mg 1 times / day multiple, oral
Highest studied dose
Dose: 420 mg, 1 times / day
Route: oral
Route: multiple
Dose: 420 mg, 1 times / day
Sources: Page: p.793
unhealthy, 66.4
n = 20
Health Status: unhealthy
Condition: Levodopa-Induced Dyskinesia in Parkinson Disease
Age Group: 66.4
Sex: M+F
Population Size: 20
Sources: Page: p.793
Constipation 5%
Disc. AE
420 mg 1 times / day multiple, oral
Highest studied dose
Dose: 420 mg, 1 times / day
Route: oral
Route: multiple
Dose: 420 mg, 1 times / day
Sources: Page: p.793
unhealthy, 66.4
n = 20
Health Status: unhealthy
Condition: Levodopa-Induced Dyskinesia in Parkinson Disease
Age Group: 66.4
Sex: M+F
Population Size: 20
Sources: Page: p.793
Dry mouth 5%
Disc. AE
420 mg 1 times / day multiple, oral
Highest studied dose
Dose: 420 mg, 1 times / day
Route: oral
Route: multiple
Dose: 420 mg, 1 times / day
Sources: Page: p.793
unhealthy, 66.4
n = 20
Health Status: unhealthy
Condition: Levodopa-Induced Dyskinesia in Parkinson Disease
Age Group: 66.4
Sex: M+F
Population Size: 20
Sources: Page: p.793
Subdural hematoma 5%
Disc. AE
420 mg 1 times / day multiple, oral
Highest studied dose
Dose: 420 mg, 1 times / day
Route: oral
Route: multiple
Dose: 420 mg, 1 times / day
Sources: Page: p.793
unhealthy, 66.4
n = 20
Health Status: unhealthy
Condition: Levodopa-Induced Dyskinesia in Parkinson Disease
Age Group: 66.4
Sex: M+F
Population Size: 20
Sources: Page: p.793
Dry mouth below serious, 4 patients
100 mg 3 times / day steady, oral
Dose: 100 mg, 3 times / day
Route: oral
Route: steady
Dose: 100 mg, 3 times / day
Sources:
unhealthy
n = 36
Health Status: unhealthy
Condition: Parkinson's disease
Population Size: 36
Sources:
OverviewDrug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
unlikely
unlikely
unlikely
unlikely
unlikely
unlikely
unlikely
unlikely
unlikely
yes [Ki 111.8 uM]
yes [Ki 1167 uM]
yes [Ki 236 uM]
yes [Ki 284 uM]
yes [Ki >1000 uM]
Drug as victim
PubMed

PubMed

TitleDatePubMed
Treatment of experimental pneumocystosis: review of 7 years of experience and development of a new system for classifying antimicrobial drugs.
1992 Sep
Synthesis of 2-(2-adamantyl)piperidines and structure anti-influenza virus A activity relationship study using a combination of NMR spectroscopy and molecular modeling.
1999 Dec 20
Cerebellar Ataxia.
2000 May
Beneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson's disease.
2000 Sep
Quetiapine for l-dopa-induced psychosis in PD.
2000 Sep 26
Novel 3-(2-adamantyl)pyrrolidines with potent activity against influenza A virus-identification of aminoadamantane derivatives bearing two pharmacophoric amine groups.
2001 Aug 20
Addition of hydrophilic and lipophilic compounds of biological relevance to the monoolein/water system. I. Phase behavior.
2001 Jan
Amantadine-induced cortical myoclonus.
2001 Jan 23
[L-dopa-induced movement disorders in Parkinson disease. Amantadine improves dyskinesia].
2001 May 28
In vitro and in vivo activities of anti-influenza virus compound T-705.
2002 Apr
Comparison of colorimetric, fluorometric, and visual methods for determining anti-influenza (H1N1 and H3N2) virus activities and toxicities of compounds.
2002 Oct
Amantadine in Huntington's disease: open-label video-blinded study.
2002 Sep
Huntington's disease: a randomized, controlled trial using the NMDA-antagonist amantadine.
2002 Sep 10
An artist's view of drug-induced hallucinosis.
2003 Jul
Mirtazapine in L-dopa-induced dyskinesias.
2003 Jul-Aug
Bitterness evaluation of medicines for pediatric use by a taste sensor.
2004 Aug
Platinum(IV) complex with adamantylamine as nonleaving amine group: synthesis, characterization, and in vitro antitumor activity against a panel of cisplatin-resistant cancer cell lines.
2004 Jan 29
New platinum(IV) complex with adamantylamine ligand as a promising anti-cancer drug: comparison of in vitro cytotoxic potential towards A2780/cisR cisplatin-resistant cell line within homologous series of platinum(IV) complexes.
2004 Jun
High effectiveness of platinum(IV) complex with adamantylamine in overcoming resistance to cisplatin and suppressing proliferation of ovarian cancer cells in vitro.
2005 Feb 1
Prediction of genotoxicity of chemical compounds by statistical learning methods.
2005 Jun
Comparative anti-tumor efficacy of two orally administered platinum(IV) drugs in nude mice bearing human tumor xenografts.
2006 Feb
[Cytosine demethylation in the tyrosine hydroxylase gene promoter in the hypothalamus cells of the rat brain under the action of an aminoadamantane derivative Ladasten].
2006 Jul
Patents

Sample Use Guides

Uncomplicated Influenza A Virus Illness: Adult: 200 mg; two 100 mg capsules as a single daily dose. The daily dosage may be split into one capsule of 100 mg twice a day. In persons 65 years of age or older, the daily dosage is 100 mg. Parkinsonism: Adult: is 100 mg twice a day when used alone. Amantadine Hydrochloride Capsules have an onset of action usually within 48 hours. The initial dose is 100 mg daily for patients with serious associated medical illnesses or who are receiving high doses of other antiparkinson drugs. After one to several weeks at 100 mg once daily, the dose may be increased to 100 mg twice daily, if necessary.
Route of Administration: Oral
Amantadine markedly inhibited the proliferation of HepG2 and SMMC‑7721 cells in a dose‑ and time‑dependent manner and arrested the cell cycle at the G0/G1 phase
Substance Class Chemical
Created
by admin
on Sat Jun 26 14:13:27 UTC 2021
Edited
by admin
on Sat Jun 26 14:13:27 UTC 2021
Record UNII
BF4C9Z1J53
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
AMANTADINE
HSDB   INN   MART.   MI   VANDF   WHO-DD  
INN  
Official Name English
GOCOVRI
Brand Name English
AMANTADINE [MI]
Common Name English
AMANTADINE [MART.]
Common Name English
AMANTADINE [VANDF]
Common Name English
ADAMANTAN-1-AMINE
Systematic Name English
AMANTADINE [INN]
Common Name English
NSC-341865
Code English
AMANTIDINE
Common Name English
AMANTADINE [WHO-DD]
Common Name English
AMANTADINE [HSDB]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C93038
Created by admin on Sat Jun 26 14:13:28 UTC 2021 , Edited by admin on Sat Jun 26 14:13:28 UTC 2021
NCI_THESAURUS C281
Created by admin on Sat Jun 26 14:13:28 UTC 2021 , Edited by admin on Sat Jun 26 14:13:28 UTC 2021
NDF-RT N0000175542
Created by admin on Sat Jun 26 14:13:28 UTC 2021 , Edited by admin on Sat Jun 26 14:13:28 UTC 2021
NCI_THESAURUS C38149
Created by admin on Sat Jun 26 14:13:28 UTC 2021 , Edited by admin on Sat Jun 26 14:13:28 UTC 2021
WHO-ATC N04BB01
Created by admin on Sat Jun 26 14:13:28 UTC 2021 , Edited by admin on Sat Jun 26 14:13:28 UTC 2021
NDF-RT N0000175543
Created by admin on Sat Jun 26 14:13:28 UTC 2021 , Edited by admin on Sat Jun 26 14:13:28 UTC 2021
WHO-VATC QN04BB01
Created by admin on Sat Jun 26 14:13:28 UTC 2021 , Edited by admin on Sat Jun 26 14:13:28 UTC 2021
LIVERTOX 33
Created by admin on Sat Jun 26 14:13:28 UTC 2021 , Edited by admin on Sat Jun 26 14:13:28 UTC 2021
Code System Code Type Description
FDA UNII
BF4C9Z1J53
Created by admin on Sat Jun 26 14:13:28 UTC 2021 , Edited by admin on Sat Jun 26 14:13:28 UTC 2021
PRIMARY
EPA CompTox
768-94-5
Created by admin on Sat Jun 26 14:13:28 UTC 2021 , Edited by admin on Sat Jun 26 14:13:28 UTC 2021
PRIMARY
IUPHAR
4128
Created by admin on Sat Jun 26 14:13:28 UTC 2021 , Edited by admin on Sat Jun 26 14:13:28 UTC 2021
PRIMARY
RXCUI
620
Created by admin on Sat Jun 26 14:13:28 UTC 2021 , Edited by admin on Sat Jun 26 14:13:28 UTC 2021
PRIMARY RxNorm
DRUG CENTRAL
144
Created by admin on Sat Jun 26 14:13:28 UTC 2021 , Edited by admin on Sat Jun 26 14:13:28 UTC 2021
PRIMARY
EVMPD
SUB05389MIG
Created by admin on Sat Jun 26 14:13:28 UTC 2021 , Edited by admin on Sat Jun 26 14:13:28 UTC 2021
PRIMARY
MESH
D000547
Created by admin on Sat Jun 26 14:13:28 UTC 2021 , Edited by admin on Sat Jun 26 14:13:28 UTC 2021
PRIMARY
INN
1816
Created by admin on Sat Jun 26 14:13:28 UTC 2021 , Edited by admin on Sat Jun 26 14:13:28 UTC 2021
PRIMARY
CAS
768-94-5
Created by admin on Sat Jun 26 14:13:28 UTC 2021 , Edited by admin on Sat Jun 26 14:13:28 UTC 2021
PRIMARY
PUBCHEM
2130
Created by admin on Sat Jun 26 14:13:28 UTC 2021 , Edited by admin on Sat Jun 26 14:13:28 UTC 2021
PRIMARY
LACTMED
Amantadine
Created by admin on Sat Jun 26 14:13:28 UTC 2021 , Edited by admin on Sat Jun 26 14:13:28 UTC 2021
PRIMARY
WIKIPEDIA
AMANTADINE
Created by admin on Sat Jun 26 14:13:28 UTC 2021 , Edited by admin on Sat Jun 26 14:13:28 UTC 2021
PRIMARY
ChEMBL
CHEMBL660
Created by admin on Sat Jun 26 14:13:28 UTC 2021 , Edited by admin on Sat Jun 26 14:13:28 UTC 2021
PRIMARY
HSDB
3202
Created by admin on Sat Jun 26 14:13:28 UTC 2021 , Edited by admin on Sat Jun 26 14:13:28 UTC 2021
PRIMARY
NCI_THESAURUS
C61632
Created by admin on Sat Jun 26 14:13:28 UTC 2021 , Edited by admin on Sat Jun 26 14:13:28 UTC 2021
PRIMARY
DRUG BANK
DB00915
Created by admin on Sat Jun 26 14:13:28 UTC 2021 , Edited by admin on Sat Jun 26 14:13:28 UTC 2021
PRIMARY
ECHA (EC/EINECS)
212-201-2
Created by admin on Sat Jun 26 14:13:28 UTC 2021 , Edited by admin on Sat Jun 26 14:13:28 UTC 2021
PRIMARY
MERCK INDEX
M1638
Created by admin on Sat Jun 26 14:13:28 UTC 2021 , Edited by admin on Sat Jun 26 14:13:28 UTC 2021
PRIMARY Merck Index
Related Record Type Details
SALT/SOLVATE -> PARENT
TRANSPORTER -> INHIBITOR
TRANSPORTER -> INHIBITOR
TRANSPORTER -> INHIBITOR
TRANSPORTER -> INHIBITOR
TRANSPORTER -> INHIBITOR
SALT/SOLVATE -> PARENT
BINDER->LIGAND
BINDING
TRANSPORTER -> SUBSTRATE
TRANSPORTER -> SUBSTRATE
Related Record Type Details
METABOLITE -> PARENT
URINE
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC